You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 140 No. 9, September 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (7)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Hematology/ Hematologic Malignancies
 •Leukemias/ Lymphomas
 •Prognosis/ Outcomes
 •Neoplasms
 •Alert me on articles by topic

Prognostic Value of Blood Eosinophilia in Primary Cutaneous T-Cell Lymphomas

Emmanuelle Tancrède-Bohin, MD; Marius Anton Ionescu, MD; Pauline de La Salmonière, MD; Alain Dupuy, MD; Jacqueline Rivet, MD; Michel Rybojad, MD; Louis Dubertret, MD; Hervé Bachelez, MD, PhD; Celeste Lebbé, MD, PhD; Patrice Morel, MD

Arch Dermatol. 2004;140:1057-1061.

Objective  To investigate the prognostic value of initial characteristics including blood eosinophilia in patients with primary cutaneous T-cell lymphoma.

Design  A retrospective inception cohort, patients included from date of diagnosis (1982-1998).

Setting  Two dermatology departments of a university hospital.

Patients  A total of 104 patients with cutaneous T-cell lymphoma, including patients with mycosis fungoides (n = 69), Sézary syndrome (n = 13), and nonepidermotropic cutaneous lymphoma (n = 22). The following variables were recorded: age, sex, diagnosis according to the European Organization for Research and Treatment of Cancer (EORTC) classification, type of skin involvement at the time of diagnosis, initial eosinophil absolute count, lactate dehydrogenase value, date of disease progression, and cause and date of death or date of last contact.

Main Outcome Measures  Time from diagnosis to disease progression and to disease-specific death.

Results  The median follow-up was 43 months (range, 7-197 months). Estimated rates of disease progression and disease-specific death for 3 years were 19.5% (95% confidence interval [CI],11.3%-27.6%) and 9.9% (95% CI, 2.8%-13.6%), respectively. Univariable analysis of initial variables possibly influencing disease progression revealed significant prognostic value for diagnosis according to EORTC classification (hazard ratio [HR], 2.77; 95% CI, 1.04-7.41; P = .04), type of skin involvement (HR, 2.70; 95% CI, 1.00-7.25; P = .04), raised blood eosinophil absolute count (HR, 7.33; 95% CI, 2.84-18.91; P<.001), and raised serum level of lactate dehydrogenase (HR, 3.72; 95% CI, 1.58-8.78; P = .001).Concerning disease-specific death, significant prognostic indicators were diagnosis according to the EORTC classification (HR, 6.62; 95% CI, 1.68-26.12; P = .007) and a raised blood eosinophil absolute count (HR, 10.57; 95% CI, 2.28-49.0; P<.001). In multivariable analysis, only blood eosinophilia was associated with disease progression and disease-specific death.

Conclusion  These results strongly suggest that blood eosinophilia at baseline is a prognostic factor in patients with primary cutaneous T-cell lymphoma.


From the Departments of Dermatology 2 (Drs Tancrède-Bohin, Ionescu, Dupuy, Rybojad, Lebbé, and Morel), Pathology (Dr Rivet), and Biostatistics (Dr de La Salmonière), Dermatology 1 (Drs Dubertret and Bachelez), Hôpital Saint-Louis, Paris, France. The authors have no relevant financial interest in this article.


RELATED ARTICLE

Neoplastic Stem Cells in Cutaneous Lymphomas: Evidence and Clinical Implications
Robert Gniadecki
Arch Dermatol. 2004;140(9):1156-1160.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.